1 day ago · Key Takeaways Ribociclib demonstrated robust long-term disease control in HR+ metastatic breast cancer, reinforcing its role in standard endocrine therapy regimens. …

3 days ago · The DESTINY-Breast09 trial compared Enhertu plus Perjeta to the standard-of-care regimen of trastuzumab (Herceptin), Perjeta, and taxane as first-line therapy for patients with …

5 days ago · Conclusions: Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L …

4 days ago · As such, there is an unmet need for developing more effective first-line maintenance treatments in HER2-positive metastatic breast cancer.

3 days ago · Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

5 days ago · The trial enrolled 654 patients with HER2-positive advanced breast cancer who had completed four to eight cycles of induction chemotherapy plus trastuzumab and pertuzumab, …

4 days ago · TUKYSA is approved in combination with trastuzumab and capecitabine to treat adults with HER2-positive advanced unresectable or metastatic breast cancer, including …

4 days ago · Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2 …

4 days ago · SAN ANTONIO — The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with HER2-positive metastatic breast …

Jan 17, 2025 · In this phase 2 basket trial, patients with heavily pretreated HER2-mutated metastatic breast cancer received the small-molecule HER2 inhibitor tucatinib and anti-HER2 …